{"nctId":"NCT02606461","briefTitle":"Selinexor in Advanced Liposarcoma","startDateStruct":{"date":"2016-01-04","type":"ACTUAL"},"conditions":["Dedifferentiated Liposarcoma"],"count":342,"armGroups":[{"label":"Phase 2 Double-blinded: Selinexor","type":"EXPERIMENTAL","interventionNames":["Drug: Selinexor"]},{"label":"Phase 3 Double-blinded: Selinexor","type":"EXPERIMENTAL","interventionNames":["Drug: Selinexor"]},{"label":"Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Selinexor","otherNames":["KPT-330"]},{"name":"Placebo","otherNames":["sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients ≥12 years of age\n2. Body surface area (BSA) ≥ 1.2 m2\n3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment\n4. Must have measurable disease per RECIST v1.1 Response Criteria\n5. Radiologic evidence of disease progression within 6 months prior to randomization. If the patient received other intervening therapy after documented disease progression, further disease progression must be documented after the completion of the intervening therapy\n6. Must have had at least 2 prior lines of systemic therapy for liposarcoma (not to exceed 5 prior lines)\n7. If patient received any previous systemic therapy, the last dose must have been ≥ 21 days prior to randomization (or ≥ 5 half-lives of that drug, whichever is shorter) with all clinically significant therapy-related toxicities having resolved to ≤ Grade 1\n\nExclusion Criteria:\n\n1. Patients with pure well-differentiated liposarcoma (WDLS), myxoid/round cell or pleomorphic tumor histologic subtypes\n2. Known active hepatitis B (HepB), hepatitis C (HepC) or human immunodeficiency virus (HIV) infection\n3. Known central nervous system metastases","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","description":"PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","spread":null},{"groupId":"OG001","value":"2.07","spread":null}]}]}]},{"type":"PRIMARY","title":"Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1","description":"PFS was defined as the time from the date of randomization in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":null}]}]}]},{"type":"PRIMARY","title":"Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1","description":"PFS was defined as the time from date of randomization until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"2.76","spread":null}]}]}]},{"type":"PRIMARY","title":"Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1","description":"PFS was defined as the time from date of randomization in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Overall Survival (OS)","description":"OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.38","spread":null},{"groupId":"OG001","value":"12.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Open Label: Overall Survival (OS)","description":"OS was defined as the duration (in months) from the date of randomization in the Phase 3 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Double Blind: Overall Survival (OS)","description":"OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.31","spread":null},{"groupId":"OG001","value":"16.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Open Label: Overall Survival (OS)","description":"OS was defined as the duration (in months) from the date of randomization in the Phase 2 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1","description":"TTP was defined as the time from date of randomization until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","spread":null},{"groupId":"OG001","value":"2.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1","description":"TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1","description":"TTP was defined as the time from date of randomization until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"2.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1","description":"TTP was defined as the time from date of randomization in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Overall Response Rate (ORR)","description":"ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Open Label: Overall Response Rate (ORR)","description":"ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Double Blind: Overall Response Rate (ORR)","description":"ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Open Label: Overall Response Rate (ORR)","description":"ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Duration of Response (DOR)","description":"DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment","description":"PFS was defined as the time from date of randomization until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":null},{"groupId":"OG001","value":"1.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Time to Next Treatment (TTNT)","description":"TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.42","spread":null},{"groupId":"OG001","value":"3.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Double Blind: Time to Next Treatment (TTNT)","description":"TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":null},{"groupId":"OG001","value":"2.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs","description":"An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Open Label: Number of Participants With TEAEs and Serious TEAEs","description":"An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Double Blind: Number of Participants With TEAEs and Serious TEAEs","description":"An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2 Open Label: Number of Participants With TEAEs and Serious TEAEs","description":"An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3 Double Blind: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)","description":"The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.22","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.67","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Phase 3 Open Label: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)","description":"The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":"NA"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":27},"commonTop":["Nausea","Decreased appetite","Fatigue","Anaemia","Vomiting"]}}}